Bausch Health Companies Inc. (NYSE:BHC) Stock Holdings Lowered by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in Bausch Health Companies Inc. (NYSE:BHC) by 7.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 318,736 shares of the company’s stock after selling 26,168 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Bausch Health Companies were worth $2,601,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. CIBC Asset Management Inc boosted its position in Bausch Health Companies by 0.3% during the 3rd quarter. CIBC Asset Management Inc now owns 374,729 shares of the company’s stock worth $3,060,000 after acquiring an additional 1,082 shares during the period. Bfsg LLC lifted its position in Bausch Health Companies by 46.7% in the 2nd quarter. Bfsg LLC now owns 11,450 shares of the company’s stock worth $80,000 after buying an additional 3,643 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Bausch Health Companies by 6.9% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 60,706 shares of the company’s stock valued at $423,000 after buying an additional 3,923 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Bausch Health Companies by 2.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 246,808 shares of the company’s stock valued at $1,719,000 after acquiring an additional 4,944 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of Bausch Health Companies during the second quarter worth $35,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Stock Performance

NYSE BHC opened at $7.81 on Friday. The stock has a 50-day simple moving average of $8.38 and a 200 day simple moving average of $7.24. The stock has a market capitalization of $2.82 billion, a PE ratio of -16.27 and a beta of 0.69. Bausch Health Companies Inc. has a twelve month low of $3.96 and a twelve month high of $11.46.

Bausch Health Companies (NYSE:BHC) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.12 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.10. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The firm had revenue of $2.51 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same quarter last year, the company earned $1.03 earnings per share. The company’s revenue for the quarter was up 12.2% compared to the same quarter last year. As a group, equities research analysts forecast that Bausch Health Companies Inc. will post 3.74 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BHC has been the topic of several research reports. Royal Bank of Canada upped their target price on Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research report on Friday, November 1st. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. Finally, Evercore ISI raised shares of Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $7.75.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.